NCT07323355 Single- vs Double-Layer Cesarean Scar Repair and Myometrial Thickness
| NCT ID | NCT07323355 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara City Hospital Bilkent |
| Condition | Caesarean Section |
| Study Type | INTERVENTIONAL |
| Enrollment | 102 participants |
| Start Date | 2025-11-11 |
| Primary Completion | 2026-09-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 102 participants in total. It began in 2025-11-11 with a primary completion date of 2026-09-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cesarean delivery (CD) is one of the most commonly performed surgical procedures worldwide, with a rising incidence particularly in high-income countries. Although often life-saving, cesarean delivery carries both short- and long-term maternal risks. Early complications include infection, hemorrhage, and thromboembolism, while inadequate uterine healing can lead to future complications such as uterine rupture and placenta accreta spectrum disorders. Additionally, cesarean scars may result in pregnancy complications, isthmocele formation, postmenstrual bleeding, pelvic pain, and dysmenorrhea. This highlights the need for optimization of the surgical technique. Despite increasing cesarean rates, there is no consensus on the optimal uterine closure method. Techniques vary in terms of the number of layers, suture locking style, and inclusion of the endometrium, and their comparative effectiveness in reducing scar defects remains unclear. Some previous studies have reported increased uterine rupture risk with single-layer locked sutures and better healing with double-layer closure, while others found no significant difference in scar outcomes. This study aims to investigate the effects of single- versus double-layer cesarean scar closure on myometrial thickness and its clinical implications.
Eligibility Criteria
Inclusion Criteria: * Female participants aged 18-44 years. * Undergoing cesarean delivery at the study hospital's Obstetrics and Gynecology clinic. * Evaluated as clinically eligible based on history, physical examination, abdominal ultrasonography, and routine preoperative laboratory tests, including: Complete blood count (CBC), biochemical profile, prothrombin time (PT), activated partial thromboplastin time (aPTT), blood group determination. No abnormalities detected in the above assessments. Exclusion Criteria: \- Presence of chronic diseases, including: Rheumatologic diseases, renal failure, vascular malformations, hypertension, cardiac disease, diabetes mellitus, obesity, thyroid disease, congenital hematologic disorders. * Suspected or confirmed placenta previa or placenta accreta spectrum. * Clinical chorioamnionitis. * Anterior wall uterine myomas. * History of low transverse nonstandard uterine incision. * Predicted obstetric hemorrhage or other intraoperative complications.
Contact & Investigator
Merve Didem Eşkin Tanrıverdi
PRINCIPAL INVESTIGATOR
Ankara City Hospital Bilkent
Frequently Asked Questions
Who can join the NCT07323355 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 44 Years, studying Caesarean Section. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07323355 currently recruiting?
Yes, NCT07323355 is actively recruiting participants. Contact the research team at mrvddm@hotmail.com for enrollment information.
Where is the NCT07323355 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07323355 clinical trial?
NCT07323355 is sponsored by Ankara City Hospital Bilkent. The principal investigator is Merve Didem Eşkin Tanrıverdi at Ankara City Hospital Bilkent. The trial plans to enroll 102 participants.